vs

Side-by-side financial comparison of CareDx, Inc. (CDNA) and IREN Ltd (IREN). Click either name above to swap in a different company.

IREN Ltd is the larger business by last-quarter revenue ($184.7M vs $117.7M, roughly 1.6× CareDx, Inc.). CareDx, Inc. runs the higher net margin — 2.4% vs -84.1%, a 86.5% gap on every dollar of revenue. On growth, IREN Ltd posted the faster year-over-year revenue change (59.0% vs 39.0%). CareDx, Inc. produced more free cash flow last quarter ($514.0K vs $-468.0M).

CareDx, Inc. is a leading precision medicine company dedicated to organ transplant patient care. It develops and commercializes diagnostic tests for rejection surveillance, digital health management tools, and supportive clinical services, catering to transplant clinicians, patients, and healthcare systems across North America and European core markets.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada.

CDNA vs IREN — Head-to-Head

Bigger by revenue
IREN
IREN
1.6× larger
IREN
$184.7M
$117.7M
CDNA
Growing faster (revenue YoY)
IREN
IREN
+20.0% gap
IREN
59.0%
39.0%
CDNA
Higher net margin
CDNA
CDNA
86.5% more per $
CDNA
2.4%
-84.1%
IREN
More free cash flow
CDNA
CDNA
$468.6M more FCF
CDNA
$514.0K
$-468.0M
IREN

Income Statement — Q1 FY2026 vs Q2 FY2026

Metric
CDNA
CDNA
IREN
IREN
Revenue
$117.7M
$184.7M
Net Profit
$2.8M
$-155.4M
Gross Margin
64.4%
Operating Margin
1.0%
-63.0%
Net Margin
2.4%
-84.1%
Revenue YoY
39.0%
59.0%
Net Profit YoY
-610.0%
EPS (diluted)
$0.05
$-0.52

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CDNA
CDNA
IREN
IREN
Q1 26
$117.7M
Q4 25
$108.4M
$184.7M
Q3 25
$100.1M
$240.3M
Q2 25
$86.7M
Q1 25
$84.7M
Q4 24
$86.6M
$116.1M
Q3 24
$82.9M
$52.8M
Q2 24
$92.3M
Net Profit
CDNA
CDNA
IREN
IREN
Q1 26
$2.8M
Q4 25
$-4.1M
$-155.4M
Q3 25
$1.7M
$384.6M
Q2 25
$-8.6M
Q1 25
$-10.4M
Q4 24
$87.7M
$-21.9M
Q3 24
$-10.6M
$-51.7M
Q2 24
$-4.6M
Gross Margin
CDNA
CDNA
IREN
IREN
Q1 26
Q4 25
64.4%
Q3 25
66.4%
Q2 25
Q1 25
Q4 24
72.2%
Q3 24
39.6%
Q2 24
Operating Margin
CDNA
CDNA
IREN
IREN
Q1 26
1.0%
Q4 25
-5.6%
-63.0%
Q3 25
-0.2%
-31.8%
Q2 25
-12.8%
Q1 25
-15.8%
Q4 24
97.5%
14.9%
Q3 24
-16.6%
-89.2%
Q2 24
-7.9%
Net Margin
CDNA
CDNA
IREN
IREN
Q1 26
2.4%
Q4 25
-3.8%
-84.1%
Q3 25
1.7%
160.1%
Q2 25
-9.9%
Q1 25
-12.2%
Q4 24
101.3%
-18.8%
Q3 24
-12.8%
-98.0%
Q2 24
-5.0%
EPS (diluted)
CDNA
CDNA
IREN
IREN
Q1 26
$0.05
Q4 25
$-0.08
$-0.52
Q3 25
$0.03
$1.08
Q2 25
$-0.16
Q1 25
$-0.19
Q4 24
$1.60
$-0.10
Q3 24
$-0.20
$-0.27
Q2 24
$-0.09

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CDNA
CDNA
IREN
IREN
Cash + ST InvestmentsLiquidity on hand
$77.9M
$3.3B
Total DebtLower is stronger
Stockholders' EquityBook value
$2.5B
Total Assets
$411.1M
$7.0B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CDNA
CDNA
IREN
IREN
Q1 26
$77.9M
Q4 25
$177.2M
$3.3B
Q3 25
$194.2M
$1.0B
Q2 25
$186.3M
Q1 25
$230.9M
Q4 24
$260.7M
$427.3M
Q3 24
$240.9M
$98.6M
Q2 24
$228.9M
Total Debt
CDNA
CDNA
IREN
IREN
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
$0
Q2 24
$0
Stockholders' Equity
CDNA
CDNA
IREN
IREN
Q1 26
Q4 25
$303.1M
$2.5B
Q3 25
$311.1M
$2.9B
Q2 25
$327.4M
Q1 25
$379.3M
Q4 24
$378.4M
$1.2B
Q3 24
$273.2M
$1.1B
Q2 24
$264.7M
Total Assets
CDNA
CDNA
IREN
IREN
Q1 26
$411.1M
Q4 25
$413.2M
$7.0B
Q3 25
$432.3M
$4.3B
Q2 25
$444.3M
Q1 25
$489.6M
Q4 24
$491.1M
$1.9B
Q3 24
$477.0M
$1.3B
Q2 24
$466.8M
Debt / Equity
CDNA
CDNA
IREN
IREN
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
0.00×
Q2 24
0.00×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CDNA
CDNA
IREN
IREN
Operating Cash FlowLast quarter
$4.3M
$71.7M
Free Cash FlowOCF − Capex
$514.0K
$-468.0M
FCF MarginFCF / Revenue
0.4%
-253.4%
Capex IntensityCapex / Revenue
292.2%
Cash ConversionOCF / Net Profit
1.54×
TTM Free Cash FlowTrailing 4 quarters
$-701.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CDNA
CDNA
IREN
IREN
Q1 26
$4.3M
Q4 25
$21.4M
$71.7M
Q3 25
$37.4M
$142.4M
Q2 25
$9.9M
Q1 25
$-26.6M
Q4 24
$21.9M
$53.6M
Q3 24
$12.5M
$-3.9M
Q2 24
$18.9M
Free Cash Flow
CDNA
CDNA
IREN
IREN
Q1 26
$514.0K
Q4 25
$-468.0M
Q3 25
$-38.0M
Q2 25
Q1 25
Q4 24
$-85.5M
Q3 24
$-109.7M
Q2 24
FCF Margin
CDNA
CDNA
IREN
IREN
Q1 26
0.4%
Q4 25
-253.4%
Q3 25
-15.8%
Q2 25
Q1 25
Q4 24
-73.6%
Q3 24
-208.0%
Q2 24
Capex Intensity
CDNA
CDNA
IREN
IREN
Q1 26
Q4 25
292.2%
Q3 25
75.0%
Q2 25
Q1 25
Q4 24
119.7%
Q3 24
200.6%
Q2 24
Cash Conversion
CDNA
CDNA
IREN
IREN
Q1 26
1.54×
Q4 25
Q3 25
22.30×
0.37×
Q2 25
Q1 25
Q4 24
0.25×
Q3 24
Q2 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CDNA
CDNA

Financial Results Total$85.0M72%
Patient and digital solutions revenue$16.0M14%
Product revenue$10.3M9%
Other$6.4M5%

IREN
IREN

Bitcoin Mining Revenue$167.4M91%
AI Cloud Services$17.3M9%

Related Comparisons